Atumelnant

Atumelnant

Clinical data
Other names	CRN04894
Routes of administration	Oral [1]
Drug class	Melanocortin MC2 receptor antagonist [1]
Identifiers
IUPAC name N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-[(2R)-2-ethyl-4-[1-(trifluoromethyl)cyclobutanecarbonyl]piperazin-1-yl]pyridine-2-carboxamide
CAS Number	2392970-97-5
PubChem CID	146361282
IUPHAR/BPS	13339
UNII	NR57FH6U1N
Chemical and physical data
Formula	C33H42F3N5O3
Molar mass	613.726 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC[C@@H]1CN(CCN1C2=C(N=C(C=C2)C3=CC=CC=C3OCC)C(=O)N[C@@H]4CN5CCC4CC5)C(=O)C6(CCC6)C(F)(F)F
InChI InChI=InChI=1S/C33H42F3N5O3/c1-3-23-20-40(31(43)32(14-7-15-32)33(34,35)36)18-19-41(23)27-11-10-25(24-8-5-6-9-28(24)44-4-2)37-29(27)30(42)38-26-21-39-16-12-22(26)13-17-39/h5-6,8-11,22-23,26H,3-4,7,12-21H2,1-2H3,(H,38,42)/t23-,26-/m1/s1 Key:QJRFBKYETDVAJQ-ZEQKJWHPSA-N

Atumelnant (INN Tooltip International Nonproprietary Name; developmental code name CRN04894) is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone (ACTH)-dependent endocrine disorders. ^[1] It is a selective antagonist of the melanocortin type 2 receptor (MC2R), also known as the ACTH receptor, which is primarily expressed in the adrenal glands. ^{[1] [2]} The drug is orally active. ^[1] Atumelnant is being evaluated to treat conditions such as congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome caused for example by pituitary adenomas. ^[3]

References

1. "Crinetics Pharmaceuticals". AdisInsight. 21 January 2025. Retrieved 25 February 2025.
2. "Atumelnant (CRN04894)". crinetics.com. 14 August 2020.
3. Varlamov EV, Gheorghiu ML, Fleseriu M (December 2024). "Pharmacological management of pituitary adenomas - what is new on the horizon?". Expert Opinion on Pharmacotherapy. doi:10.1080/14656566.2024.2446625. PMID   39718553.